Latest Prostate Cancer News

Page 3 of 6
Radiopharm Theranostics has secured ethics approval to begin a Phase 1 clinical trial of RAD 402, a pioneering radiotherapeutic targeting advanced prostate cancer using terbium-161. This marks a significant step in developing a potentially safer, more effective treatment option.
Ada Torres
Ada Torres
18 Nov 2025
Clarity Pharmaceuticals has bolstered its financial position with a $203 million institutional placement and reported positive Phase II trial results for its lead prostate cancer diagnostic, Cu-SAR-bisPSMA. The company also expanded its pipeline with promising preclinical data on a pan-cancer agent and secured a key copper-67 supply agreement to support future commercialisation.
Ada Torres
Ada Torres
31 Oct 2025
LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.
Ada Torres
Ada Torres
29 Oct 2025
Radiopharm Theranostics has secured FDA approval to initiate a Phase I trial targeting B7H3 and raised A$40 million to accelerate its radiopharmaceutical programs. The company also appointed renowned oncologist Dr Oliver Sartor to its Scientific Advisory Board.
Ada Torres
Ada Torres
28 Oct 2025
Orthocell has raised $30 million through an institutional placement to accelerate the US commercialisation of its flagship nerve repair product Remplir and expand its regenerative medicine portfolio.
Ada Torres
Ada Torres
17 Oct 2025
Clarity Pharmaceuticals has inked a pivotal supply agreement with Nusano to ensure a steady source of copper-67, a critical isotope for its upcoming Phase III prostate cancer trial and future commercialisation plans.
Ada Torres
Ada Torres
16 Oct 2025
Telix Pharmaceuticals reports a robust 53% revenue jump in Q3 2025 and raises its full-year guidance, underpinned by key reimbursement wins and expanding clinical programs.
Ada Torres
Ada Torres
14 Oct 2025
Clarity Pharmaceuticals’ Co-PSMA Phase II trial shows its Cu-SAR-bisPSMA diagnostic agent detects more prostate cancer lesions than current standard imaging, promising earlier and more accurate recurrence detection.
Ada Torres
Ada Torres
14 Oct 2025
Orthocell Limited has reported a record $3 million quarterly revenue, driven by strong sales of its nerve repair product Remplir in Australia and Singapore, while advancing its rollout in the US and Canada ahead of schedule.
Ada Torres
Ada Torres
10 Oct 2025
Telix Pharmaceuticals secures Transitional Pass-Through payment status for its next-generation prostate cancer imaging agent Gozellix, paving the way for broader US patient access and streamlined provider reimbursement.
Ada Torres
Ada Torres
23 Sept 2025
Orthocell’s nerve repair device Remplir is being adopted in Australia for nerve-sparing prostate cancer surgeries, aiming to reduce erectile dysfunction and urinary incontinence post-operation. This development could significantly expand Remplir’s market reach globally.
Ada Torres
Ada Torres
16 Sept 2025
Proteomics International has unveiled new clinical data confirming its PromarkerEso blood test can accurately detect early stages of esophageal adenocarcinoma, potentially transforming screening for a cancer with poor prognosis.
Ada Torres
Ada Torres
8 Sept 2025